Home > Vitamins > Senior's Health >

Slow the Process of Alzheimer's Disease - Acetyl-L-carnitine Extremely Helpful - Article
Slow the Process of Alzheimer's Disease - Acetyl-L-carnitine Extremely Helpful - Article

Slow the Process of Alzheimer's Disease - Acetyl-L-carnitine Extremely Helpful - Article
Our Price:



Clinical and neurochemical effects of acetyl-L-carnitine in Alzheimer's disease

LifeSource Vitamins

Acetyl-L-carnitine: A drug able to slow the progress of Alzheimer's disease?

ANN. NEW YORK ACAD. SCI. (USA), 1991, 640/- (228-232)

Defects in cholinergic neurotransmission do not, by themselves, constitute the sole pathophysiologic concomitants of Alzheimer's disease (AD). Recent findings point out that abnormalities in membrane phospholipid turnover and in brain energy metabolism may also characterize AD. Acetyl-L-carnitine (ALC) is an endogenous substance that, acting as an energy carrier at the mitochondrial level, controls the availability of acetyl-L-CoA. ALC has a variety of pharmacologic properties that exhibit restorative or even protective actions against aging processes and neurodegeneration. A review of a series of controlled clinical studies suggests that ALC may also slow the natural course of AD.

Pharmacokinetics of IV and oral acetyl-L-carnitine in a multiple dose regimen in patients with senile dementia of Alzheimer Type

EUR. J. CLIN. PHARMACOL. (Germany), 1992, 42/1 (89-93)

Acetyl-L-carnitine (ALC), a physiological component of the L-carnitine family, has been proposed for treating Alzheimer's disease in pharmacological doses. As this condition requires prolonged therapy, its kinetics has been examined after a multiple dose regimen, involving different routes of administration, in 11 patients suffering from Senile Dementia of Alzheimer Type. The study design comprised a 3-day basal observation period, sham treatment with repeated blood sampling; treatment with 30 mg.kg-1 i.v. given twice for 10 days (plasma kinetics was studied on the 7th day), and 50 days of 2.0 g/day p.o. given in three daily doses. Total acid soluble L-carnitine, L-carnitine and acetyl-L-carnitine in plasma and CSF were evaluated using an enantioselective radioenzyme assay. Short chain L-carnitine esters were calculated as the difference between total and free-L-carnitine. The plasma concentrations of individual components of the L-carnitine family did not change during the three days of the basal period, nor were they affected during the sham therapy period. Following the i.v. bolum injections, the plasma concentrations showed a biphasic curve, with average t(one-half) of 0.073 h and 1.73 h, respectively. At the end of oral treatment, plasma acetyl-L-carnitine and L-carnitine short chain esters were significantly higher than during the run-in phase. The CSF concentrations paralleled those in plasma, suggesting that ALC easily crosses the blood-brain barrier. It is concluded that i.v. and oral administration of multiple doses of ALC can increase its plasma and CSF concentration in patients suffering from Alzheimer's disease.

Double-blind, placebo-controlled study of acetyl-l-carnitine in patients with Alzheimer's disease

CURR. MED. RES. OPIN. (United Kingdom), 1989, 11/10 (638-647)

A randomized, double-blind, placebo-controlled, parallel-group clinical trial was carried out to compare 24-week periods of treatment with 1 g acetyl-l-carnitine twice daily and placebo in the treatment of patients with dementia of the Alzheimer type. A total of 36 patients entered the trial, of whom 20 patients (7 active, 13 placebo) completed the full 24 weeks. Whilst several of the efficacy indices showed little change in either group during the trial, there was an apparent trend for more improvement in the acetyl-l-carnitine group in relation to the Names Learning Test and a computerized Digit Recall Test, both related to aspects of short-term memory. Similarly, there was a trend for reaction time in the computerized classification test to show less deterioration in the active treatment group. Changes within groups, and changes between groups, failed to reach statistical significance, at least partially because of the small number of patients available for analysis. Two indices of overall therapeutic benefit showed a trend for less deterioration in the active-treatment group than in the placebo group. Nausea and/or vomiting occurred in 5 patients in the acetyl-l-carnitine group. Laboratory tests revealed no signs of drug toxicity. The results suggest that acetyl-l-carnitine may have a beneficial effect on some clinical features of Alzheimer-type dementia, particularly those related to short-term memory.

Click here to see all
Acetyl L-Carnitine at LifeSource Vitamins

Proudly Made in the USA!

Every LifeSource Vitamins product exceeds all regulatory standards and requirements set forth in the FDA's Code of Federal Regulation. ( 21 CFR, part 111 ) as well as all Good Manufacturing Practices enforced by the FDA. CGMP's provide for systems that assure proper design, monitoring, and control of manufacturing processes and facilities. ( CGMP ).

LifeSource Vitamins: Driven by Faith ~ Powered by God

Have Questions on this or any other product or health issue for you or a loved one? It can be overwhelming we know. Call us, we will walk you through what supplements will help you and which ones you really don’t need. It’s what we do! Toll-Free: 800-567-8122

LifeSource Vitamins – Founded in 1992

100% of our profits are donated to Christian Organizations like these and many others worldwide:

Campus Crusade for Christ - CRU

The Jesus Film Project

World Vision

The Tim Tebow Foundation

Compassion International

Samaritan’s Purse

The Herman and Sharron Show on CTN (Christian Television Network) and many more…


E-mail Us: info@LifesourceVitamins.com

or Call Us: 800.567.8122

We Are Built on Compassion - Driven by Faith & Powered by God!

*Disclaimer: None of the above statements have been evaluated by the FDA. These products are not intended to diagnose, treat, cure or prevent any disease. As always, consult your physician before taking any and all supplements. LifeSource Vitamins. Individual results may vary.

Disclaimer: All the information contained throughout this website is based upon the opinions of the founder of LifeSource Vitamins, Bruce Brightman, and the entire team at LifeSource Vitamins whose relentless research and studies have been ongoing since 1992. Other articles and information are based on the opinions of the authors, who retain the copyright as marked in the article. The information on this site is not intended to replace your health care professional, but to enhance your relationship with them. Doing your own studying and research and taking your health care into your own hands is always best, especially in partnership with your health care professional.

If you are pregnant, nursing, taking medications, or have any medical conditions, always consult your health care professional before taking supplements based on the information on this site.

LifeSource Vitamins: from the nutrients we choose, to the way we run our business, we answer to God in all we do!